Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Fabian Ortiz

Physician Assistant Bronx, NY Physician Assistant

NPI 1609511427 CMS profile 11309529

119 E Fordham Rd, Bronx, NY 10468

Open in the dashboard

General payments

$8,303

209 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Fabian Ortiz of Bronx, NY is reported in the CMS Open Payments database as having received $8,303 across 209 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,975 77
2024 General $754 13
2023 General $2,359 66
2022 General $2,216 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fabian Ortiz
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Fabian Ortiz were reported at $2,975. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Fabian Ortiz Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $2,216 $155 $48–$522 $149
2023 $2,359 $167 $52–$557 $160
2024 $754 $178 $55–$600 $164
2025 $2,975 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $1,055 46 payments
  2. Incyte Corporation $864 18 payments
  3. Genzyme Corporation $668 14 payments
  4. Lilly USA, LLC $627 12 payments
  5. Regeneron Healthcare Solutions, Inc. $562 17 payments
  6. Janssen Biotech, Inc. $519 4 payments
  7. UCB, Inc. $490 12 payments
  8. Arcutis Biotherapeutics, Inc. $459 24 payments
  9. Pfizer Inc. $451 11 payments
  10. LEO Pharma Inc. $428 11 payments
  11. Other $2,180 40 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $8,006 206 payments
  2. Education $297 3 payments
Products named General payments · program years 2022–2025
  1. TREMFYA $880 7 payments
  2. OPZELURA $864 18 payments
  3. DUPIXENT Immunology $845 17 payments
  4. RINVOQ $649 27 payments
  5. Bimzelx $490 12 payments
  6. DUPIXENT Inflammation And Immunology $469 11 payments
  7. CIBINQO $451 11 payments
  8. Zoryve $317 17 payments
  9. ADBRY $276 9 payments
  10. SKYRIZI $256 17 payments
  11. Other $2,702 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

872

Median for Physician Assistant: 241

Drug cost

$268,341

Median for Physician Assistant: $4,110

Branded share of claims

10.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 33 $121,478
Opzelura Ruxolitinib Phosphate Brand 48 $91,547
Vtama Tapinarof Brand 13 $17,825
Tacrolimus Generic 73 $14,708
Clobetasol Propionate Generic 39 $4,003
Hydrocortisone Generic 67 $2,679
Calcipotriene Generic 13 $2,563
Clotrimazole Generic 61 $2,189
Metronidazole Generic 20 $1,793
Clindamycin Phosphate Generic 27 $1,716

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPZELURA
  • Incyte Corporation $276
$276 48 —
TREMFYA
  • Janssen Biotech, Inc. $100
  • Janssen Scientific Affairs, LLC $92
$192 — —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $127
$127 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $98
$98 33 —
SKYRIZI
  • AbbVie, Inc. $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

209 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record